In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern.
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) / Zito, C., Manganaro, R., Cusmà Piccione, M., Madonna, R., Monte, I., Novo, G., Mercurio, V., Longobardo, L., Cadeddu Dessalvi, C., Deidda, M., Pagliaro, P., Spallarossa, P., Costantino, R., Santarpia, M., Altavilla, G., Carerj, S., Tocchetti, C.G.. - In: EUROPEAN HEART JOURNAL. CARDIOVASCULAR IMAGING. - ISSN 2047-2404. - (2021). [10.1093/ehjci/jeaa339]
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC)
Mercurio, Valentina;Pagliaro, Pasquale;Tocchetti, Carlo Gabriele
2021
Abstract
In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern.| File | Dimensione | Formato | |
|---|---|---|---|
|
2021 zito jeaa339.pdf
solo utenti autorizzati
Licenza:
Accesso privato/ristretto
Dimensione
490.72 kB
Formato
Adobe PDF
|
490.72 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
